Endocare Inc

Endocare — C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference 2006

17 slides from Endocare's conference presentation, Oct 27, 2006

  1. Slide 1: Endocare, Inc. C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference

    Endocare, Inc. C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference October 30, 2006 201 Technology Drive Irvine, California 92618 (949) 450-5400

  2. Slide 2: Forward-Looking Statements, etc.

    Forward-Looking Statements, etc. Statements contained in this presentation that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements

  3. Slide 3: Topics

    Topics Craig T. Davenport CEO, President & Chairman Our Vision Statement Cancer Facts Financial Performance Why Endocare?

  4. Slide 4: Our Vision

    Our Vision Endocare is focused on improving the health and quality of patients' lives through safe, cost effective, proprietary cryoablation technologies for treating cancerous tissue and tumors.

  5. Slide 5: 2006 Estimated U.S. Cancer Cases

    * Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder. Source: American Cancer Society, 2006. Men 720,280 Women 679,510 Prostate 33% Lung and bronchus 13% Colon and rectum 10% Urinary bladder 7% Melanoma of skin 5% Non-Hodgkin's 4% lymphoma Kidney 3% Leukemia

  6. Slide 6: Prostate Cancer Basics

    Prostate Cancer Basics 234,000 treatable cases per year in the U.S. 27,350 deaths estimated in 2006 Most early prostate cancer has no symptoms USUALLY relatively slow growth but some tumors rapid growth Metastasizes to lymph nodes, bone, liver, lung Cure or significant prolongation is possible if ca

  7. Slide 7: Renal or Kidney Cancer Basics

    Renal or Kidney Cancer Basics 35,000 treatable cases per year in the U.S. 12,840 deaths Most often diagnosed in those 50-70 years of age No blood test (diagnostic like PSA) for kidney cancer 70% of cancers found on incidental CT or MRI Blood in urine is the most common sign of kidney cancer 106 Indi

  8. Slide 8: Endocare Markets Cryoablation Technology

    Endocare Markets Cryoablation Technology Oncology, Radiology Interventional Radiology Liver Tumors Lung Tumors Kidney Tumors Prostate Cancer Kidney Cancer Urology

  9. Slide 9: Current Cryo Systems (The "Razor")

    TM Current Cryo Systems (The "Razor") CryoCare CryoCare TM

  10. Slide 10: CryoProbe (Razor Blades)

    CryoProbe (Razor Blades) Urology Interventional Radiology Features Multiple Probe System Right Angle design CT-compatible Fits under CT Gantry Tumors easily targeted Wide grip handle Components 6 - 2.4 mm CryoProbes 6 - TemProbes Warming Catheter

  11. Slide 11: Endocare Domestic Cryoablation Procedures

    Endocare Domestic Cryoablation Procedures 1,546 3,554 2,479 2002 - 2005 Actual and 1st Nine Months 2006 4,720 6,550 0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 2003 2004 2005 9 Months 2006 5,578 2002 3,504 2,474 4,713 6,407

  12. Slide 12: Summary Annual Financial Data (From Continuing Operations)

    Summary Annual Financial Data (From Continuing Operations) ($000's) 2003 2004 2005 2006 Total revenues 19,604 $ 24,181 $ 28,274 $ 14,170 $ Gross margin % 41.4% 43.8% 44.3% 50.5% SG&A expenses 41,888 $ 29,733 $ 26,859 $ 13,740 $ Cash used in operations (23,623) $ (17,088) $ (14,718) $ (7,413) $ (Unau

  13. Slide 13: Quarterly Domestic Procedural Growth

    Quarterly Domestic Procedural Growth * 3rd Quarter 2006 Data Are Estimated and Have Not Yet Been Reported

  14. Slide 14: Summary Unaudited Quarterly Financial Data

    Summary Unaudited Quarterly Financial Data * 3rd Quarter 2006 Data Are Estimated and Have Not Yet Been Reported ($000's) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Total revenues 6,867 $ 6,919 $ 7,008 $ 7,481 $ 7,262 $ 6,908 $ * Gross margin % 39.0% 43.3% 45.6% 48.9% 48.1% 52.9% * SG&A expenses 6,849 $ 6,478 $ 6,646 $ 6,

  15. Slide 15: Other Significant Events

    Other Significant Events Capital Financing Update... During Investor 3rd Qtr Call, in early November Anticipate addressing EBITDA Breakeven date.

  16. Slide 16: Why Endocare?

    Historically rapid procedural growth. Clinically proven (10-year clinical results) technology for tissue and tumor ablation. Strong IP in large markets with less than 4% current market share. Growing market acceptance among physicians, academics, patients and payers. Gross margins, net income and op

  17. Slide 17: Thank you for your interest & consideration

    Thank you for your interest & consideration ENDOCARE - endo.ob

Endocare — C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference 2006 on 6ix